Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021

Cited by 387 works. doi:10.1016/s1470-2045(21)00065-6

Authors

References